Demographic and clinical characteristics of included patients (n=98)
| Age, years | 29 (22–40) |
| Body weight at admission, kg | 48 (44–58) |
| Body weight after 8 months of treatment, kg (n=85) | 56 (47–60) |
| Gender, male (n=98) | 56 (57.1) |
| Comorbidity (n=80) | |
| HIV | 6 (7.5) |
| Diabetes mellitus | 6 (7.5) |
| Seizure disorder | 4 (5.0) |
| Cardiovascular disease | 1 (1.3) |
| Active hepatitis/cirrhosis | 1 (1.3) |
| Osteoporosis | 1 (1.3) |
| Gastric ulcer | 1 (1.3) |
| Diagnosis (n=96) | |
| Sputum | 92 (95.8) |
| Others (pleural fluid, lymph node aspirate) | 4 (4.2) |
| Radiographic findings (n=83) | |
| Cavitary lesions | 7 (8.4) |
| Bilateral pulmonary involvement with cavitary lesions | 10 (12.1) |
| Bilateral pulmonary involvement without cavitary lesions | 31 (37.4) |
| Non-cavitary non-bilateral pulmonary involvement | 33 (39.8) |
| Normal chest finding | 2 (2.4) |
| Drug resistance, phenotypic testing | |
| Streptomycin (n=14) | 13 (92.9) |
| Isoniazid (n=24) | 24 (100) |
| Rifampicin (n=88) | 88 (100) |
| Ethambutol (n=74) | 39 (52.7) |
| Drug resistance, genotypic testing | |
| Isoniazid (n=9), InhA wildtype and katG Mut 1 | 9 (100) |
| Rifampicin (n=9), rpoB (mutation-3) | 9 (100) |
| Ethambutol (n=74), emB-Mut1 | 38 (51.4%) |
Categorical data are expressed in frequencies and percentages whereas continuous variables are presented as median and IQR.